title: Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
abstract: The immunogenicity of adenovirus serotype 5 (Ad5) vectors has been shown to be suppressed by neutralizing antibodies (NAbs) directed primarily against the hexon hypervariable regions (HVRs). We previously reported that replacing all seven HVRs with those from the rare serotype virus Ad48 resulted in a chimeric Ad5HVR48(1-7) vector that largely evaded preexisting Ad5 immunity in mice and rhesus monkeys. In this study, we evaluated the extent to which Ad5-specific NAbs are directed against various HVRs. We constructed partial HVR-chimeric Ad5 vectors with only a subset of HVRs exchanged, and we utilized these vectors in both NAb assays and murine immunogenicity studies with and without baseline Ad5 immunity. Our results demonstrate that Ad5-specific NAbs target multiple HVRs, suggesting that replacing all HVRs is required to optimize evasion of anti-Ad5 immunity. These data have important implications for the development of novel vectors for both vaccines and gene therapy.
authors.affiliation: Division of Vaccine Research, Beth Israel Deaconess Medical Center, and Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
authors.forename: Ritu R
authors.initials: RR
authors.lastname: Bradley
authors.forename: Lori F
authors.initials: LF
authors.lastname: Maxfield
authors.forename: Diana M
authors.initials: DM
authors.lastname: Lynch
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Iampietro
authors.forename: Erica N
authors.initials: EN
authors.lastname: Borducchi
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
mesh_terms: D000258:Adenovirus Infections, Human / Q000276:immunology* / Q000821:virology; D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D015316:Genetic Therapy / Q000295:instrumentation; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009500:Neutralization Tests
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; C018315:hexon capsid protein, Adenovirus
references.citation: Annu Rev Med. 2004;55:355-72
references.pmid: 14746526
references.citation: J Clin Invest. 2010 Oct;120(10):3688-701
references.pmid: 20811151
references.citation: Virology. 2010 Nov 10;407(1):1-6
references.pmid: 20797754
references.citation: J Virol. 2003 Oct;77(19):10366-75
references.pmid: 12970421
references.citation: Nature. 2003 Aug 7;424(6949):681-4
references.pmid: 12904795
references.citation: J Gene Med. 2009 Jul;11(7):570-9
references.pmid: 19391169
references.citation: Lancet. 2008 Nov 29;372(9653):1881-1893
references.pmid: 19012954
references.citation: Virology. 1996 Oct 15;224(2):357-67
references.pmid: 8874497
references.citation: Nature. 2002 Jan 17;415(6869):331-5
references.pmid: 11797011
references.citation: J Virol. 1998 Mar;72(3):2388-97
references.pmid: 9499099
references.citation: Lancet. 2008 Nov 29;372(9653):1894-1905
references.pmid: 19012957
references.citation: Science. 2010 Aug 27;329(5995):1038-43
references.pmid: 20798312
references.citation: J Virol. 2003 Aug;77(15):8263-71
references.pmid: 12857895
references.citation: Hum Gene Ther. 2004 Dec;15(12):1167-76
references.pmid: 15684694
references.citation: Emerg Infect Dis. 2006 Oct;12(10):1596-9
references.pmid: 17176582
references.citation: Vaccine. 2011 Jul 18;29(32):5203-9
references.pmid: 21619905
references.citation: Science. 2010 Aug 27;329(5995):1071-5
references.pmid: 20798318
references.citation: Nature. 2006 May 11;441(7090):239-43
references.pmid: 16625206
references.citation: J Immunol. 2005 Jun 1;174(11):7179-85
references.pmid: 15905562
references.citation: J Virol. 2010 Oct;84(20):10522-32
references.pmid: 20686035
references.citation: Hum Gene Ther. 2002 Jan 20;13(2):311-20
references.pmid: 11812286
references.citation: J Virol. 2006 Dec;80(24):11991-7
references.pmid: 17005652